Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 1M | 2M | 24M | 61M |
| Gross Profit | -3M | -3M | -2M | 21M | 59M |
| Operating Income | -49M | -43M | -38M | -29M | -13M |
| EBITDA | 17M | -29M | -38M | -15M | -15M |
| Net Income | 13M | -34M | -42M | -19M | -17M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$4.00
+3.63% today
1Y Change
+88.07%
Window
Jun 23, 2025 → Jun 10, 2026
Coverage: 243 bars · Jun 23, 2025 → Jun 10, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SAB Biotherapeutics, Inc. (SABS) is a Healthcare stock with a market cap of $40.00M and listed on NASDAQ. The stock last traded around $4.00 and up 88.1% across the available one-year price window (Jun 23, 2025 → Jun 10, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +106.0%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +106.0%, free cash flow -32.0% with operating margin 0.0% and ROIC -30.0%. Valuation is more restrained than many high-expectation growth names at P/E 5.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SABS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SABS
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SABS Max Drawdown
-33.80%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SABS and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$60.9M
+154.7% YoY
FY Net Income
-$17.1M
+8.5% YoY
Free Cash Flow
-$9.0M
+65.0% YoY
Revenue Growth
-100.0%
EPS Growth
+106.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 1M | 2M | 24M | 61M |
| Gross Profit | -3M | -3M | -2M | 21M | 59M |
| Operating Income | -49M | -43M | -38M | -29M | -13M |
| EBITDA | 17M | -29M | -38M | -15M | -15M |
| Net Income | 13M | -34M | -42M | -19M | -17M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 11M | 9M | 57M | 15M | 33M |
| Total Assets | 173M | 44M | 84M | 51M | 81M |
| Total Liabilities | 21M | 18M | 27M | 20M | 43M |
| Shareholder Equity | 151M | 26M | 57M | 31M | 39M |
| Total Debt | 6M | 5M | 6M | 6M | 9M |
| Net Debt | -5M | -4M | -51M | -9M | -25M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2M
+108.5% YoY
Capital Expenditures
11M
-405.2% YoY
Free Cash Flow
9M
+65.0% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
15.2%
Debt / Equity
0.04x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.